Table 3.
Characteristics of COVID-19 patients with elevated pancreatic enzyme levels during remdesivir treatment.
| Patients characteristics (N = 23) | N | (%) |
|---|---|---|
| Age, years, median (range) | 73 (50–91) | |
| Sex | ||
| Male | 14 | 60.9 |
| Female | 9 | 39.1 |
| Race | ||
| Japanese | 21 | 91.3 |
| East-Asian | 2 | 8.7 |
| Smoking history | ||
| Never smoker | 10 | 43.5 |
| Ex-smoker | 4 | 17.4 |
| Current smoker | 5 | 21.7 |
| Unknown | 4 | 17.4 |
| History of alcohol consumption | ||
| Regular drinking | 8 | 34.8 |
| Drinking on occasion | 2 | 8.7 |
| Never | 6 | 26.1 |
| Unknown | 7 | 30.4 |
| Comorbidities | ||
| Diabetes mellitus | 10 | 43.5 |
| Hypertension | 13 | 56.5 |
| Hyperlipidemia | 5 | 21.7 |
| Severity of illness categories by NIH classification | ||
| Severe | 8 | 34.8 |
| Critical | 15 | 65.2 |
| Duration of remdesivir administration, days | ||
| 2 | 2 | 8.7 |
| 5 | 17 | 73.9 |
| 7 | 1 | 4.3 |
| 10 | 3 | 13.0 |
| Duration from COVID-19 onset to remdesivir administration, days, median (range) | 5 (1–9) | |
| Steroid dose | ||
| Steroid pulse | 16 | 69.6 |
| Non-pulse | 6 | 26.1 |
| No | 1 | 4.3 |
| Duration of steroid administration, days, median (range) | 12.5 (5–69) | |
| Outcome | ||
| Discharged | 20 | 88.1 |
| Death | 2 | 8.7 |
| Hospitalized | 1 | 4.3 |
| Duration of hospitalization, days, median, (range) | 16 (4–65) | |